Biologic Drug Reduces Symptoms, Hospitalization for Severe Pulmonary Hypertension After Diagnosis

Sept. 30, 2025
Read time: <5 mins
Resize Image Project 2025 10 04T211628.041

A University of Michigan-led study is giving new hope to people newly diagnosed with pulmonary arterial hypertension (PAH), a serious condition affecting the heart and lungs. Led by Dr. Vallerie McLaughlin of Michigan Medicine, the research points to a treatment approach that could help patients live longer, healthier lives. Learn how this breakthrough could change the future of PAH care.

Share:
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.